A Play On BIOTECH

24 de mai. de 2016

Here's the thing.. whether you like it or not the Stock Market is heading higher and if you really wanna maximize your upside potential then BIOTECH is where you should park some of your money. Biotech is very much on the move but I would wait for a bounce off the trendline to buy back in -- Momentum is on our side but RSI/Stochastics are showing a tad overbought in the short to medium term.

Ps: And if your balls are made of steel then you might want to take a look at LABU to further capitalize on any potential gains.

9 de jun. de 2016

Nota

XBI traded and closed below its 10DMA today and could be looking for a correction. I will be looking to buy back in [via LABU] once RSI/TSI reaches oversold levels, and Price finds support around $54 -- give or take a dollar. The 100DMA should also provide support as well.

Ps: Carl Icahn sold his Apple shares and reinvested in Bio/Pharma. A good omen!

14 de jun. de 2016

Nota

Right on target.. XBI could drop a little more over the next couple of days but I will definitely be buying in if we get a retest of $54.. And possibly once more if we are fortunate enough to get Price/RSI/TSI bullish divergence like we did back in May 2016. Also worth mentioning.. with tomorrow's FOMC meeting and Brexit looming, things could get a little hazy! Hang tight.

16 de jun. de 2016

Nota

LONG LABU @$30. Will pick up some more if the Market decides to retest the current lows.

21 de jun. de 2016

Nota

Another incredible buying opportunity. XBI just tagged trendline support and the 100DMA.

Picking up more LABU @$27

14 de jul. de 2016

Nota

XBI couldn't break through the 200 DMA and could as a result correct all the way back down to $54.. which means that I will look to sell some of my LABU shares tomorrow at the open [probably should've done it today but oh well] and look to reload when my RSI/TSI indicator has dropped into 'oversold' territory.

Big picture: I am LONG Biotech but would like to buy at the bottom of the range, just in case this consolidation continues to drag on a little longer than expected. Hopefully I won't get left behind :/ but at the same time, it's important to adapt to an ever changing environment.

14 de jul. de 2016

Nota

Option #2 -- Keep your current shares and buy the dips or move to an un-leveraged position!